Linifanib Fails to Meet Overall Survival Endpoint for Advanced Hepatocellular Carcinoma
the Cancer Therapy Advisor take:
According to a new study published in the Journal of Clinical Oncology, linifanib and sorafenib had similar overall survival for the treatment of patients with advanced hepatocellular carcinoma (HCC), while sorafenib was more safe.
For the open-label phase 3 study, researchers enrolled 1,035 patients with a median age of 60 years old with advanced HCC and randomly assigned them to receive linifanib 17.5mg orally once daily or sorafenib 400mg orally twice daily.
Linifanib is a novel, potent tyrosine kinase inhibitor currently under development by Abbott Laboratories. Of those enrolled, 66.6% were Asian, 65.2% had an ECOG performance score of 0, 49.1% had hepatitis B infection, and 70.1% had vascular invasion or extrahepatic spread.
Results showed a median overall survival of 9.1 months (95% CI: 8.1 - 10.2) with linifanib and 9.8 months (95% CI: 8.3 - 11.0; HR = 1.046; 95% CI: 0.896 - 1.221) with sorafenib. The median time to progression was found to be 5.4 months (95% CI: 4.2 - 5.6) and 4.0 months (95% CI: 2.8 - 4.2: HR = 0.759; 95% CI: 0.643 - 0.895; P = 0.001).
In addition, objective response rates were 13.0% in the linifanib group and 6.9% in the sorafenib group. In regard to safety, serious adverse effects were more common in the linifanib arm and were more likely to cause discontinuation and dose modification (P < 0.001).
Linifanib and sorafenib had similar overall survival for the treatment of advanced HCC.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Ginkgo Biloba and Cancer
- Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC
- Curative-intent Surgery for Cancer Increases Risk of New Persistent Opioid-use
- HIV-associated Head and Neck Cancers Have Unique Molecular Characteristics
- Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC
- Cost, Insurance Status May Affect Patient Adherence to TKI Therapy for CML
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured